Trial Profile

A Phase Ib Study of RVU120 (SEL120) in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 13 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs RVU 120 (Primary)
Indications Acute myeloid leukaemia; Myelodysplastic syndromes
Focus Adverse reactions; First in man
Acronyms RIVER-51
Sponsors Ryvu Therapeutics

Most Recent Events

14 Jun 2024 According to a Ryvu Therapeutics media release,Results presented at the 2024 European Hematology Association Congress (EHA), June 13-16, Madrid, Spain.
29 Jan 2024 Planned End Date changed from 30 Dec 2023 to 30 Dec 2024.
29 Jan 2024 Planned primary completion date changed from 30 Dec 2023 to 30 Dec 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com